Ichnos Glenmark Innovation (IGI), a wholly-owned subsidiary of GlenmarkPharmaceuticals, has entered into an exclusive global licensing agreementwith AbbVie for the development and commercialization of IGI’s leadoncology asset, ISB 2001. This first-in-class CD38×BCMA×CD3 trispecificantibody is currently in Phase 1 clinical trials for relapsed/refractory multiplemyeloma (R/R MM).